Tag: NYSE:MRK

February 5, 2020

Merck Announces Q4 and Full-Year 2019 Financial Results

Merck reported quarterly sales at US$11.9 billion in Q4 in its financial results for the fourth quarter of 2019 and...
January 6, 2020

Pharma Outlook 2020: Oncology Commands Sector Growth

At the dawn of a new year, INN offers a preview of potential developments in the pharmaceutical market throughout 2020.
January 2, 2020

Biotech Outlook 2020: Washington Scrutiny Looms Over Sector

INN offers a closer look at the path ahead for biotech investors in 2020 as new challenges arise for the...
December 23, 2019

Pharma Trends 2019: FDA Approvals Make Waves Through Market

INN takes a look at the pharma trends of 2019 that have shaken up the space this year and created...
November 12, 2019

NewLink Genetics Receives European Commission Grant of Conditional Marketing Approval for V920

The European Commission has granted a conditional marketing authorization to ERVEBO, an investigational V920 Ebola Zaire vaccine.
October 15, 2019

Blockchain Update: Q3 2019 in Review

In this blockchain update, INN highlights the major trends that took place over the third quarter, from hedging to institutionalization.
September 18, 2019

NewLink Genetics Receives FDA Acceptance for Partnered Biologics License Application

NewLink Genetics (NASDAQ:NLNK) has announced that the US Food and Drug Administration has accepted Merck’s (NYSE:MRK)’s Biologics License Application and...